Skip to content
Menu

Craig-Hallum Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $16

Benzinga Newsdesk 11 hours ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Craig-Hallum analyst Adam Vogel initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $16.

Craig-Hallum analyst Adam Vogel initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $16.

Read at benzinga.com

← All stock news